Adecatumumab (MT201) is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has been shown to promote the proliferation, migration and invasiveness of breast cancer cells. Moreover, expression of EpCAM is associated with decreased survival in a number of cancer indications, including breast, gall bladder, bile duct, ovarian and ampullary pancreatic cancer. EpCAM has recently been shown to be expressed on cancer stem cells from breast, prostate, colon and pancreatic cancer. Clinical studies have shown a favorable safety profile and that clinical activity depends on the EpCAM target expression.
Format
Fully human antibody
Target
EpCAM
Status
Ongoing phase 2 clinical trial in CRC
Ongoing phase 1 clinical trial in breast cancer; MT201 in combination with TaxotereŽ
Collaboration Partner
Merck Serono
Clinical Results
Posters at SABCS, ASCO and ESMO Publications in Eur J Cancer and Annals of Oncology
